Gastrointestinal stromal tümörler: Tek merkez deneyimi-demografik ve patolojik bulguların analizi

Year 2025, Volume: 16 Issue: 2, 315 - 321, 30.06.2025

Selahattin Çelik , Engin Eren Kavak

https://doi.org/10.18663/tjcl.1695720

Abstract

Amaç: Gastrointestinal stromal tümörler (GİST), gastrointestinal sistemin en sık görülen mezenkimal neoplazmları olup sıklıkla mide ve ince bağırsaktan kaynaklanmaktadır. Nadir görülmelerine rağmen, son yıllarda moleküler biyoloji ve hedefe yönelik tedavi alanındaki gelişmeler klinik sonuçları anlamlı düzeyde iyileştirmiştir. Bu tek merkezli retrospektif çalışmanın amacı, GİST tanısı almış hastaların demografik, patolojik ve tedaviye ilişkin özelliklerini değerlendirmek; rekürrenssiz sağkalım (RFS) süresini ve tedaviye bağlı tolerabiliteyi gerçek yaşam koşullarında incelemektir.

Gereç ve Yöntemler: Eylül 2022 ile Eylül 2024 tarihleri arasında Ankara Etlik Şehir Hastanesi'nde GİST tanısı almış hastaların tıbbi kayıtları retrospektif olarak incelenmiştir. Demografik özellikler, tümör lokalizasyonu, mitotik indeks, immünohistokimyasal belirteçler, KIT/PDGFRA mutasyon durumu, cerrahi ve sistemik tedavi verileri, advers olaylar ve sağkalım sonuçları analiz edilmiştir. RFS, tedavi başlangıcından itibaren nüks, ölüm veya son takip tarihine kadar geçen süre olarak tanımlanmıştır.

Bulgular: Toplam 46 hasta çalışmaya dahil edilmiş olup, ortanca yaş 62,9 yıl (aralık: 41,8–82,0) ve %58,7’si erkekti. Tümörlerin en sık yerleşim yerleri mide (%60,9) ve ince bağırsak (%34,8) idi. Tüm hastalara cerrahi rezeksiyon uygulanmış, %84,8’inde R0 rezeksiyon sağlanmıştır. Hastaların %58,7’sine adjuvan imatinib tedavisi verilmiş, bu grubun %19,6’sında advers etki bildirilmiştir. Ortanca 16,8 aylık takip süresi boyunca 4 hastada (%8,7) nüks saptanmış, 1 hasta (%2,2) yaşamını yitirmiştir. Ortanca RFS’ye ulaşılamamıştır. Tümör boyutu, rezeksiyon durumu ve diğer klinik değişkenler ile RFS arasında tek değişkenli analizde istatistiksel olarak anlamlı ilişki saptanmamıştır.

Sonuç: Bu çalışma, GİST hastalarının gerçek yaşam verilerine dayalı klinik ve patolojik özelliklerine ışık tutmaktadır. Bulgular literatürle büyük ölçüde uyumlu olsa da, hasta sayısının sınırlı oluşu ve kısa takip süresi nedeniyle uzun dönem prognostik faktörlerin daha net belirlenebilmesi için prospektif ve çok merkezli çalışmalara ihtiyaç duyulmaktadır.

Keywords

GİST , İmatinib , progresyon , yan etki

Ethical Statement

Etik onay, Ankara Etlik Şehir Hastanesi Klinik Araştırmalar Etik Kurulu tarafından alınmıştır (Karar No: AEŞH- BADEK1-2025-077).

Supporting Institution

Araştırmacıların herhangi bir çıkar ilişkisi bulunmamaktadır. Çalışmayı maddi olarak destekleyen kişi/kuruluş yoktur.

Gastrointestinal stromal tumors analysis of demographic and pathological findings: Single center experience

Abstract

Aim: Gastrointestinal stromal tumors (GISTs) represent the most common mesenchymal neoplasms of the gastrointestinal tract, frequently arising from the stomach and small intestine. Despite their rarity, recent advances in molecular biology and targeted therapies have significantly improved clinical outcomes. This single-center retrospective study aimed to characterize the demographic, pathological, and treatment-related features of patients diagnosed with GIST, and to evaluate recurrence-free survival (RFS) and treatment tolerability under real-world clinical conditions.

Material and Methods: We retrospectively reviewed medical records of patients diagnosed with GIST at Ankara Etlik City Hospital between September 2022 and September 2024. Data regarding demographic characteristics, tumor localization, mitotic index, immunohistochemical profile, KIT/PDGFRA mutation status, surgical outcomes, targeted therapy administration, adverse events, and survival metrics were analyzed. RFS was defined as the time from treatment initiation to recurrence, death, or last follow-up.

Results: A total of 46 patients were included, with a median age of 62.9 years (range: 41.8–82.0); 58.7% were male. The most common tumor sites were the stomach (60.9%) and small intestine (34.8%). All patients underwent surgical resection, with R0 resection achieved in 84.8%. Adjuvant imatinib therapy was administered to 58.7% of patients, and adverse effects were reported in 19.6% of those treated. During a median follow-up of 16.8 months, recurrence occurred in 4 patients (8.7%) and 1 patient (2.2%) died. Median RFS was not reached. Tumor size, resection margin status, and other clinical variables showed no statistically significant association with RFS in univariate analysis.

Conclusions: This study provides insight into the clinical and pathological characteristics of GIST patients in a real-world setting. While the findings are largely consistent with existing literature, the limited sample size and short follow-up period underscore the need for prospective, multicenter studies to better define long-term prognostic factors and optimize treatment strategies.

Keywords

GIST , Imatinib , progression , side effects

References

• Joensuu H. Gastrointestinal stromal tumor (GIST). Ann Oncol 2006; 17: 280-6.
• Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, Jemal A. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2024; 74: 229-63.
• Stamatakos M, Douzinas E, Stefanaki C, Safioleas P, Polyzou E, Levidou G, Safioleas M. Gastrointestinal stromal tumor. World J Surg Oncol 2009; 7: 61.
• Demetri GD, von Mehren M, Antonescu CR, DeMatteo RP, Ganjoo KN, Maki RG et al. NCCN Task Force report: update on the management of patients with gastrointestinal stromal tumors. J Natl Compr Canc Netw 2010; 8(2 Suppl): S1-41; quiz S2-4.
• Caterino S, Lorenzon L, Petrucciani N, Iannicelli E, Pilozzi E, Romiti A et al. Gastrointestinal stromal tumors: correlation between symptoms at presentation, tumor location and prognostic factors in 47 consecutive patients. World J Surg Oncol 2011; 9: 1-10.
• King DM. The radiology of gastrointestinal stromal tumours (GIST). Cancer Imaging 2005; 5: 150.
• Miettinen M, Lasota J. Gastrointestinal stromal tumors: review on morphology, molecular pathology, prognosis, and differential diagnosis. Arch Pathol Lab Med 2006; 130: 1466-78.
• Joensuu H, DeMatteo RP. The management of gastrointestinal stromal tumors: a model for targeted and multidisciplinary therapy of malignancy. Annu Rev Med 2012; 63: 247-58.
• Blay JY, Kang YK, Nishida T, von Mehren M. Gastrointestinal stromal tumours. Nat Rev Dis Primers 2021; 7: 22.
• Joensuu H, Hohenberger P, Corless CL. Gastrointestinal stromal tumour. Lancet 2013; 382: 973-83.
• von Mehren M, Joensuu H. Gastrointestinal Stromal Tumors. J Clin Oncol 2018; 36: 136-43.
• Miettinen M, Sobin LH, Lasota J. Gastrointestinal stromal tumors of the stomach: a clinicopathologic, immunohistochemical, and molecular genetic study of 1765 cases with long-term follow-up. Am J Surg Pathol 2005; 29: 52-68.
• Nilsson B, Bümming P, Meis-Kindblom JM, Odén A, Dortok A, Gustavsson B et al. Gastrointestinal stromal tumors: the incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era--a population-based study in western Sweden. Cancer 2005; 103: 821-9.
• Swallow CJ. The enduring decision-making role of the surgeon in the multidisciplinary management of GIST. Ann Oncol 2022; 33: 17-9.
• von Mehren M, Kane JM, Riedel RF, Sicklick JK, Pollack SM, Agulnik M et al. NCCN Guidelines® insights: gastrointestinal stromal tumors, version 2.2022: featured updates to the NCCN guidelines. J Natl Compr Canc Netw 2022; 20: 1204-14.
• Badic B, Gancel CH, Thereaux J, Joumond A, Bail JP, Meunier B, Sulpice L. Surgical and oncological long term outcomes of gastrointestinal stromal tumors (GIST) resection-retrospective cohort study. Int J Surg 2018; 53: 257-61.
• Casali PG, Blay JY, Abecassis N, Bajpai J, Bauer S, Biagini R et al. Gastrointestinal stromal tumours: ESMO–EURACAN–GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2022; 33: 20-33.
• Joensuu H, Trent JC, Reichardt P. Practical management of tyrosine kinase inhibitor-associated side effects in GIST. Cancer Treat Rev 2011; 37: 75-88.
• Thanopoulou E, Judson I. The safety profile of imatinib in CML and GIST: long-term considerations. Arch Toxicol 2012; 86: 1-12.
• Dematteo RP, Gold JS, Saran L, Gönen M, Liau KH, Maki RG et al. Tumor mitotic rate, size, and location independently predict recurrence after resection of primary gastrointestinal stromal tumor (GIST). Cancer 2008; 112: 608-15.
• Deshaies I, Cherenfant J, Gusani NJ, Jiang Y, Harvey HA, Kimchi ET et al. Gastrointestinal stromal tumor (GIST) recurrence following surgery: review of the clinical utility of imatinib treatment. Ther Clin Risk Manag 2010: 453-8.
• Klug LR, Khosroyani HM, Kent JD, Heinrich MC. New treatment strategies for advanced-stage gastrointestinal stromal tumours. Nat Rev Clin Oncol 2022; 19: 328-41.
• Farag S, Smith MJ, Fotiadis N, Constantinidou A, Jones RL. Revolutions in treatment options in gastrointestinal stromal tumours (GISTs): The latest updates: Revolutions in treatment options in GIST. Curr Treat Options Oncol 2020; 21: 1-11.